Idarubicin Intravenous and Ogivri Injection
Determining the interaction of Idarubicin Intravenous and Ogivri Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ask your doctor before using IDArubicin together with trastuzumab. This can cause damage to the heart. Heart function and drug levels in the blood may be monitored with blood tests during treatment. Call your doctor if you experience difficulty breathing, fluid retention, or chest pain. You may need a dose adjustment to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline class are individually cardiotoxic and may have additive effects during coadministration. Since trastuzumab has a half-life of approximately 28 to 38 days, it may persist in the circulation for up to 27 weeks after stopping treatment. Thus, the use of anthracyclines after stopping trastuzumab may also carry a higher risk of cardiac toxicity.
MANAGEMENT: Trastuzumab and cardiotoxic agents such as anthracyclines should not be used in combination except in settings where cardiac monitoring is possible. The use of anthracycline-based therapy should be avoided, if possible, for up to 7 months after stopping trastuzumab. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. DOXOrubicin Hydrochloride (DOXOrubicin)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
- Strasser F, Betticher DC, Suter TM "Trastuzumab and breast cancer." N Engl J Med 345 (2001): 996
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA.
Generic Name: idarubicin
Brand name: Idamycin PFS, Idamycin
Synonyms: Idarubicin, IDArubicin
Generic Name: trastuzumab
Brand name: Herceptin, Kanjinti, Ogivri
Synonyms: Ogivri
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Idarubicin Intravenous-Ogivri Intravenous
- Idarubicin Intravenous-Ohm Allergy Relief
- Idarubicin Intravenous-Olanzapine
- Idarubicin Intravenous-Olanzapine and Fluoxetine
- Idarubicin Intravenous-Olanzapine and Fluoxetine Capsules
- Idarubicin Intravenous-Olanzapine Extended-Release Injection
- Ogivri Injection-Idelalisib
- Ogivri Injection-Idelvion
- Ogivri Injection-Idelvion Intravenous
- Ogivri Injection-Idhifa
- Ogivri Injection-Iferex 150
- Ogivri Injection-Ifex